

Minimal Residual Disease - ALL Programme
All Participant Report

Sample - 078

Distribution - 161704

Participant ID - 4XXXX

Date Issued - 24 January 2017

Closing Date - 13 February 2017

Machine Used - Facs Canto II

Trial Comments

This trial was issued to 110 participants
Please note that from this trial onwards, the z score limits have been altered to 2.5 and 3.5.

Sample Comments

The sample was manufactured by UK NEQAS using a B-ALL patient sample and a stabilised whole blood unit

Results and Performance

Percentage MRD Population	Your Results (%)	Robust Mean (%)	Robust SD (%)
	0.4015	0.1646	0.0245

Percentage MRD Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
	9.67	Critical	8	1	3

***z Score Limits Definitions**


Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts.



Histograms of Participant z Scores



Percentage MRD Population -
Please note ▼ denotes your result




Minimal Residual Disease - ALL Programme

 Sample - 078

Shewhart Control Charts

(Please note each data point represents a single sample)


Values (Percentage MRD Population)



Cusum Control Charts

(Please note each data point represents the sum of the z scores of the current sample and the two previous samples)

Values (Percentage MRD Population)



Minimal Residual Disease - ALL Programme

 Sample - 078Flow Cytometer Specific Statistics

(Please note only groups of >10 returns are displayed)

Method	Count Values (%)		
	Returns	Robust Mean	Robust SD
Facs Canto II	64	0.1594	0.0232
Navios	22	0.1705	0.0187

MRD Group Specific Statistics

(Please note only groups of >10 returns are displayed)

Method	Count Values (%)		
	Returns	Robust Mean	Robust SD
IBFM	28	0.1691	0.0158
Non-Affiliated	47	0.1629	0.0221

Minimal Residual Disease - ALL Programme

Sample - 079

Distribution - 161704

Participant ID - 4XXXX

Date Issued - 24 January 2017

Closing Date - 13 February 2017

Machine Used - Facs Canto II

Trial Comments

This trial was issued to 110 participants

Please note that from this trial onwards, the z score limits have been altered to 2.5 and 3.5.

Sample Comments

The sample was manufactured by UK NEQAS using a B-ALL patient sample and a stabilised whole blood unit

Results and Performance

Percentage MRD Population	Your Results (%)	Robust Mean (%)	Robust SD (%)
	0.1376	0.0509	0.0091

Percentage MRD Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
	9.53	Critical	7	1	4

***z Score Limits Definitions**


Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts.



Histograms of Participant z Scores

Percentage MRD Population -

Please note ▼ denotes your result




Minimal Residual Disease - ALL Programme

Sample - 079

Shewhart Control Charts

(Please note each data point represents a single sample)


Values (Percentage MRD Population)



Cusum Control Charts

(Please note each data point represents the sum of the z scores of the current sample and the two previous samples)

Values (Percentage MRD Population)



Minimal Residual Disease - ALL Programme

Sample - 079

Flow Cytometer Specific Statistics

(Please note only groups of >10 returns are displayed)

Method	Count Values (%)		
	Returns	Robust Mean	Robust SD
Facs Canto II	64	0.0502	0.0093
Navios	22	0.0501	0.0069

MRD Group Specific Statistics

(Please note only groups of >10 returns are displayed)

Method	Count Values (%)		
	Returns	Robust Mean	Robust SD
IBFM	28	0.0528	0.0068
Non-Affiliated	47	0.0495	0.0093

Information with respect to compliance with standards BS EN ISO/IEC 17043:2010

4.8.2 a) The proficiency testing provider for this programme is:

UK NEQAS for Leucocyte Immunophenotyping

Pegasus House, 4th Floor Suite

463A Glossop Road

Sheffield, S10 2QD

United Kingdom

Tel: +44 (0) 114 267 3600, Fax: +44 (0) 114 267 3601

e-mail: nicola.rose@ukneqasli.co.uk

4.8.2 b) The coordinators of UK NEQAS LI programmes are Prof David Barnett and Mr Liam Whitby.

4.8.2 c) Person(s) authorizing this report:

Prof David Barnett, Director or Mr Liam Whitby, Operations Manager of UK NEQAS LI

4.8.2 d) No activities in relation to this EQA exercise were subcontracted.

4.8.2 g) The UK NEQAS LI Confidentiality Policy can be found in the Quality Manual which is available by contacting the UK NEQAS LI office. Participant details, their results and their performance data remain confidential unless revealed to the relevant NQAAP when a UK participant is identified as having performance issues.

4.8.2 i) All EQA samples are prepared in accordance with strict Standard Operational Procedures by trained personnel proven to ensure homogeneity and stability. Where appropriate/possible EQA samples are tested prior to issue. Where the sample(s) issued is stabilised blood or platelets, pre and post stability testing will have proved sample suitability prior to issue.

4.8.2 l), n), o), r) & s) Please refer to the UK NEQAS LI website at www.ukneqasli.co.uk for detailed information on each programme including the scoring systems applied to assess performance (for BS EN ISO/IEC 17043:2010 accredited programmes only). Where a scoring system refers to the 'consensus result' this means the result reported by the majority of participants for that trial issue. Advice on the interpretation of statistical analyses and the criteria on which performance is measured is also given. Please note that where different methods/procedures are used by different groups of participants these may be displayed within your report, but the same scoring system is applied to all participants irrespective of method/procedure used.

4.8.2 m) We do not assign values against reference materials or calibrants.

4.8.2 q) Details of the programme designs as authorized by The Steering Committee and Specialist Advisory Group can be found on our website at www.ukneqasli.co.uk. The proposed trial issue schedule for each programme is also available.

4.8.2 t) If you would like to discuss the outcomes of this trial issue, please contact UK NEQAS LI using the contact details provided. Alternatively, if you are unhappy with your performance classification for this trial, please find the appeals procedure at www.ukneqasli.co.uk/contact-us/appeals-and-complaints/